Analyst Profile

Followed by 354 followers
.
Boris Peaker

Boris Peaker

Cowen & Co.
Wall Street Analyst
#83 out of 8,166 Wall Street Analysts
#160 out of 24,458 experts

Success Rate

49%
202 out of 416 transactions made a profit

Average Return

+28.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Boris Peaker's trades since 2011 and holding each position for 1 Year would result in 48.56% of your transactions generating a profit, with an average return of 28.7% per rating.

Stock Rating Distribution

901Ratings
69.59% Buy
30.41% Hold
0.00% Sell
Distribution of Boris Peaker's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
Trillium Therapeutics
(TRIL)
Rating:Buy
Date:Jan 07, 2020 - Jan 07, 2021
Return:+800.00%
The most profitable rating made by Boris Peaker

Boris Peaker's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Pluri
May 17, 2011
Buy
Initiated
$5.00
(504.74% Upside)
1Ratings
0.00%
Corcept Therapeutics
Mar 27, 2012
Buy
Reiterated
$9.00
(-61.54% Downside)
1Ratings
0.00%
Aeterna Zentaris
Aug 16, 2012
Hold
Reiterated
1Ratings
0.00%
PBTH
Prolor Biotech
Aug 29, 2012
Buy
Initiated
1Ratings
0.00%
CELG
Celgene
Oct 15, 2012
Hold
Downgraded
1Ratings
0.00%
ARNA
Arena Pharma
Mar 04, 2013
Hold
Reiterated
1Ratings
0.00%
Protalix Biotherapeutics
Mar 19, 2013
Buy
Reiterated
$7.00
(488.24% Upside)
1Ratings
0.00%
Vericel
Mar 27, 2013
Hold
Reiterated
1Ratings
0.00%
RPTP
Raptor Pharmaceutical Corp.
Sep 25, 2013
Hold
Downgraded
2Ratings
0.00%
IMMU
Immunomedics
Oct 02, 2013
Buy
Reiterated
1Ratings
0.00%
List of latest recommendations made by Boris Peaker. Click to expand and see Boris Peaker's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >